betahistine dihydrochloride

DRUG5 trials

Sponsors

Intas Pharmaceuticals Limited, University of Cincinnati, OBEcure Ltd., Abbott Products, Ludwig-Maximilians - University of Munich

Conditions

Gait or Balance Disorder ProblemsMenière's diseaseMénière's DiseaseObesityRecurrent Major Depressive Disorder With Atypical Features

Phase 1

Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers

CompletedNCT05938517

Ludwig-Maximilians - University of MunichMénière's Disease

Start: 2021-06-02End: 2021-10-14Updated: 2023-07-12

Phase 2

Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features

TerminatedNCT00585585

University of CincinnatiRecurrent Major Depressive Disorder With Atypical Features

Start: 2007-07-31End: 2011-01-31Updated: 2017-07-25

Efficacy Study of Betahistine on Body Weight in Obese Female Subjects

CompletedNCT00748436

OBEcure Ltd.Obesity

Start: 2008-09-30End: 2009-04-30Updated: 2009-05-07

Phase 3

A Multicenter, Two-arm, Double-blind, Double dummy, Parallel-group Study for efficacy and safety evaluation of prolonged release formulation of Betahistine PR 48 mg once daily in comparison with conventional release formulation of Betahistine IR 24 mg, twice daily in treatment of adult patients with Menière's disease

RecruitingCTIS2024-518347-38-00

Intas Pharmaceuticals LimitedMenière's disease

Start: 2022-06-08Target: 328Updated: 2025-12-09

Phase 4

The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow

CompletedNCT01468285

Abbott ProductsGait or Balance Disorder Problems

Start: 2012-02-29End: 2013-04-30Updated: 2017-10-26

Related Papers

Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans—a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST)

Frontiers in Neurology2023-10-1812 citations